Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

NCT00798252 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: Capecitabine
DRUG: Doxorubicin
DRUG: Ixabepilone
DRUG: Docetaxel
DRUG: Paclitaxel
DRUG: Brivanib alaninate

Sponsor

Bristol-Myers Squibb